Botulotoxin in hernia surgery

Czech version

Authors: J. Novotný ¹; A. Haninec ¹; R. Tarnoczy ²
Authors‘ workplace: Chirurgické oddělení, AGEL Středomoravská nemocniční a. s. – Nemocnice AGEL Přerov ¹; Radiodiagnostické oddělení, AGEL Středomoravská nemocniční a. s. – Nemocnice AGEL Přerov ²
Published in: Rozhl. Chir., 2026, roč. 105, č. 7, s. 353-359.
Category: Case Report
doi: https://doi.org/10.48095/ccrvch2026353

Overview

Introduction: Large complex ventral hernias with the loss of domain (LOD) are one of the most challenging areas of hernia surgery due to the technical difficulty of the surgical procedures, the high risk of complications, limited possibilities of abdominal wall reconstruction and the complex primary closure of the fascia. Surgical procedures used in abdominal wall reconstruction have recently made significant progress. As part of preoperative preparation, the application of botulinum toxin type A into the lateral muscle groups of the abdominal wall is increasingly used as one of the methods. The effect of botulinum toxin causes temporary paralysis of muscle fibers, increases the compliance of the fascia and subsequently reduces the transverse dimension of the defect, which facilitates its closure.

Case report: The case report outlines our experience with preoperative application of botulinum toxin type A in a patient with a primary ventral hernia associated with the LOD phenomenon. Botulinum toxin injection into the three layers of the lateral abdominal muscles was performed four weeks before the operation aiming to achieve temporary paralysis of the muscle fibers. This procedure contributed to an increase in the volume of the abdominal cavity and a reduction in the transverse dimension of the hernial defect, as confirmed by a CT imaging. Finally, abdominal reconstruction was performed using the Rives-Stoppa method. The patient’s postoperative course was uneventful, with no complications observed.

Conclusion: This case report aims to demonstrate the use of botulinum toxin in the management of large abdominal wall hernias, as well as to highlight its potential benefits in borderline cases, where it may serve as an alternative to more invasive procedures such as component separation. We also emphasize the importance of a comprehensive evaluation of the hernia, extending beyond the simple measurement of defect width. Botulinum toxin represents a straightforward, minimally invasive, and clinically effective technique that is increasingly expanding therapeutic options available in modern hernia surgery.

Keywords:

primary ventral hernia – loss of domain – botulinum toxin type A – hernioplasty Rives-Stoppa

Sources

1. Parker SG, Halligan S, Liang MKet al. Definitions for loss of domain: an international delphi consensus of expert surgeons. World J Surg 2020; 44 (4): 1070–1078. doi: 10.1007/s00268-019-05317-z.

2. Holihan JL, Askenasy EP, Greenberg JA et al. Component separation vs. bridged repair for large ventral hernias: a multi--institutional risk-adjusted comparison, systematic review, and meta-analysis. Surg Infect (Larchmt) 2016; 17 (1): 17–26. doi: 10.1089/sur.2015.124.

3. Pous-Serrano S, Bueno-Lledó J, García--Pastor P et al. Use of botulinum toxin type A in the prehabilitation of abdominal wall musculature for hernia repair: a consensus proposal. Cir Esp (Engl Ed) 2024; 102 (7): 391–399. doi: 10.1016/j.cireng.2023.12.003.

4. Škach J, Harcubová R, Petráková V et al. Program monstrózních kýl v Kýlním centru Liberec. Rozhl Chir 2016; 95 (5): 177–187.

5. de Jong DL, Wegdam JA, Van der Wolk Set al. Prevention of component separation in complex abdominal wall surgery by Botox prehabilitation: a propensity-matched study. Hernia 2024; 28 (3): 815–821. doi: 10.1007/s10029-023-02929-2.

6. Whitehead-Clarke T, Windsor A. The use of botulinum toxin in complex hernia surgery: achieving a sense of closure. Front Surg 2021; 8 : 753889. doi: 10.3389/fsurg.2021.753889.

7. Opavský R, Otruba P, Vysloužil M et al. Spasticita horní končetiny –⁠ modulace terapií botulotoxinem typu A a odraz v kortikální somatosenzitivní aktivaci. Cesk Slov Neurol N 2011; 74/107 (1): 54–59.

8. Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol 2012; 15 (3): 325–336. doi: 10.1016/j.mib.2012.05.012.

9. Zendejas B, Khasawneh MA, Srvantstyan B et al. Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs. World J Surg 2013; 37 (12): 2830–2837. doi: 10.1007/s00268-013-2211-6.

10. López-Cano M, Armengol-Carrasco M. Chemical component separation using botulinum toxin. In: Novitsky YW (ed). Hernia surgery: current principles. Cleveland, USA: Springer International Publishing 2016 : 421–436.

11. Farooque F, Jacombs AS, Roussos E et al. Preoperative abdominal muscle elongation with botulinum toxin A for complex incisional ventral hernia repair. ANZ J Surg 2016; 86 (1–2): 79–83. doi: 10.1111/ans.13258.

12. Bueno-Lledó J, Martinez-Hoed J, Torregrosa-Gallud A et al. Botulinum toxin to avoid component separation in midline large hernias. Surgery 2020; 168 (3): 543–549. doi: 10.1016/j.surg.2020.04.050.

13. Weissler JM, Lanni MA, Tecce MG et al. Chemical component separation: a systematic review and meta-analysis of botulinum toxin for management of ventral hernia. J Plast Surg Hand Surg 2017; 51 (5): 366–374. doi: 10.1080/2000656X.2017.1285783.

14. Ibarra-Hurtado TR, Nuño-Guzmán CM, Echeagaray-Herrera JE et al. Use of botulinum toxin type a before abdominal wall hernia reconstruction. World J Surg 2009; 33 (12): 2553–2556. doi: 10.1007/s00268-009-0203-3.

15. Parker SG, Halligan S, Blackburn S et al. What exactly is meant by “loss of domain” for ventral hernia? Systematic review of definitions. World J Surg 2019; 43 (2): 396–404. doi: 10.1007/s00268-018-4783-7.

16. Parker SG, Halligan S, Liang MK et al. Definitions for loss of domain: an international delphi consensus of expert surgeons. World J Surg 2020; 44 (4): 1070–1078. doi: 10.1007/s00268-019-05317-z.

17. Al Sadairi AR, Durtette-Guzylack J, Renard A et al. A simplified method to evaluate the loss of domain. Hernia 2022; 26 (3): 927–936. doi: 10.1007/s10029-021-02474-w.

18. Love MW, Davis S, Blackhurst D et al. Rectus to defect ratio for estimating the complexity of ventral hernia repair: Is it reliable for robotic surgery? Am J Surg 2023; 226 (6): 917–920. doi: 10.1016/j.amjsurg.2023.10.021.

19. Radu V, Lica M. The endoscopic retromuscular repair of ventral hernia: the eTEP technique and early results. Hernia 2019; 23 (5): 10.1007/s10029-019-01931-x.

20. Popescu GA, Minca DG, Jafal NM et al. Multimodal prehabilitation in major abdominal surgery –⁠ rationale, modalities, results and limitations. Medicina (Kaunas) 2025; 61 (5): 908. doi: 10.3390/medicina61050908.

21. Sohan PR, Mahakalkar C, Kshirsagar S et al. Rives-stoppa repair versus bilateral inguinal hernioplasty: a comprehensive review of surgical techniques and patient outcomes. Cureus 2024; 16 (7): e65439. doi: 10.7759/cureus.65439.

22. Dias ER, Rondini GZ, Amaral PH et al. Systematic review and meta-analysis of the pre-operative application of botulinum toxin for ventral hernia repair. Hernia 2023; 27 (4): 807–818. doi: 10.1007/s10029-023-02816-w.

23. van Rooijen MM, Yurtkap Y, Allaeys M et al. Fascial closure in giant ventral hernias after preoperative botulinum toxin A and progressive pneumoperitoneum: a systematic review and meta-analysis. Surgery 2021; 170 (3): 769–776. doi: 10.1016/j.surg.2021.03.027.

24. Wegdam JA, de Vries Reilingh TS, Bouvy ND et al. Prehabilitation of complex ventral hernia patients with Botulinum: a systematic review of the quantifiable effects of Botulinum. Hernia 2021; 25 (6): 1427–1442. doi: 10.1007/s10029-020-02333-0.

25. Zwaans WA, Timmer AS, Boermeester MA. Preoperative botulinum toxin-A injections prior to abdominal wall reconstruction can lead to cardiopulmonary complications. J Abdom Wall Surg 2024; 3 : 13433. doi: 10.3389/jaws.2024.13433.

26. Zielinski MD, Goussous N, Schiller HJet al. Chemical components separation with botulinum toxin A: a novel technique to improve primary fascial closure rates of the open abdomen. Hernia 2013; 17 (1): 101–107. doi: 10.1007/s10029-012-0995-1.

27. Elstner KE, Read JW, Saunders J et al. Selective muscle botulinum toxin A component paralysis in complex ventral hernia repair. Hernia 2020; 24 (2): 287–293. doi: 10.1007/s10029-019-01939-3.

28. Timmer AS, Ibrahim F, Claessen JJ et al. Comparison of two versus three bilateral botulinum toxin injections prior to abdominal wall reconstruction. J Abdom Wall Surg 2023; 2 : 11382. doi: 10.3389/jaws.2023.11382.

29. Timmer AS, Claessen JJ, Atema JJ et al. A systematic review and meta-analysis of technical aspects and clinical outcomes of botulinum toxin prior to abdominal wall reconstruction. Hernia 2021; 25 (6): 1413–1425. doi: 10.1007/s10029-021-02499-1.